Trial Profile
Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 22 Jun 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Jul 2023.
- 18 Feb 2023 Results assessing safety and efficacy of of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer presented at the 2023 Genitourinary Cancers Symposium
- 07 Jul 2022 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.